Clinical Trial Update: A Study to Compare Eribulin Mesylate + Pertuzumab + Trastuzumab With Paclitaxel or Docetaxel + Pertuzumab + Trastuzumab [Phase 3]

View source ↗

Summary

A Phase 3 breast cancer trial comparing eribulin mesylate + pertuzumab + trastuzumab versus paclitaxel or docetaxel + pertuzumab + trastuzumab has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer

Drugs mentioned

• DOCETAXEL (DOCETAXEL)
• Eribulin mesylate (Halaven) (eribulin)
• PACLITAXEL (PACLITAXEL)
• Pertuzumab (Perjeta) (pertuzumab)
• Trastuzumab (Herceptin) (trastuzumab)

Snippet

Sponsor: Japan Breast Cancer Research Group | Conditions: Breast Cancer | Phase 3 | Status: COMPLETED